Copyright © 2021. Inderes Oyj. All rights reserved.
Käyttäjätili

Hei anonyymi!

Luomalla maksuttoman Inderes-tilin, pääset käsiksi Inderesin analyysiin, voit tilata suositun aamukatsauksen ja seurata sinua kiinnostavia yhtiöitä sekä keskusteluita.

Luo tili

Onko sinulla jo Inderes-tili?

Herantis Pharma

Sisäpiirin kaupat

Nettovaikuttavuus

Muut analyysit
20.12.
2022

Redeye endorses today’s news that Herantis has submitted a clinical trial application for a phase I study with its lead candidate HER-096 targeting Parkinson’s disease.

Muut analyysit
26.8.
2022

Redeye comments on yesterday’s H1 report from Herantis and we reiterate our view of the company.

Muut analyysit
11.7.
2022

Redeye has a positive take on the news that Antti Vuolanto, currently COO, has been named as CEO of Herantis.

Muut analyysit
16.6.
2022

Redeye comments on the recent news in the company and adjust for the recent capital injections in the company.

Muut analyysit
30.3.
2022

Redeye comments on the news that Herantis has carried out a directed issue and announced the intention to carry out a rights issue worth in total EUR 8.7 million.

Muut analyysit
4.3.
2022

Redeye comments on the H2 report from Herantis Pharma and reiterate our view of the company.

Muut analyysit
21.1.
2022

Redeye comments on yesterday’s CEO change in Herantis and announcement of strategy shift towards its next generation xCDNF program.

Muut analyysit
28.10.
2021

Redeye has an overall positive take on the progress presented at yesterday’s R&D Seminar. We give our view of the way forward for Herantis lead projects addressing Parkinson’s Disease (rhCDNF and HER-096).

Muut analyysit
16.9.
2021

Redeye comments on yesterday’s directed share issue of EUR 4 million.

Muut analyysit
9.9.
2021

Summary of events in H1’21Updated model following refocusing on CNSUpcoming milestonesDuring H1’21, Herantis decided to focus all resources on its CDNF and xCDNF assets and not pursue further development of Lymfactin, instead seeking to out-license t

Herantis Pharma